Oral Care Ingredient Dosage Form Flexibility Urged By P&G, Pfizer
This article was originally published in The Rose Sheet
Executive Summary
Category I active ingredient dosage forms other than those reviewed by the Dental Plaque Subcommittee should be allowed in the antiplaque/antigingivitis final monograph, according to Pfizer